These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23503714)

  • 41. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E; Moosbauer W; Pinter M; Mair R; Tulzer G
    Pediatr Crit Care Med; 2007 Jan; 8(1):61-3. PubMed ID: 17149153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
    Parissis JT; Panou F; Farmakis D; Adamopoulos S; Filippatos G; Paraskevaidis I; Venetsanou K; Lekakis J; Kremastinos DT
    Am J Cardiol; 2005 Aug; 96(3):423-6. PubMed ID: 16054474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
    Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
    Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension.
    Lobo Martínez P; Oulego Erroz I; Gautreux Minaya S; Rodríguez Fernández LM
    Pediatr Cardiol; 2011 Oct; 32(7):1012-6. PubMed ID: 21744292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure.
    Yilmaz MB; Yontar C; Erdem A; Karadas F; Yalta K; Turgut OO; Yilmaz A; Tandogan I
    Heart Vessels; 2009 Jan; 24(1):16-21. PubMed ID: 19165563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
    Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
    Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intermittent levosimendan infusions in advanced heart failure: a real world experience.
    Ortis B; Villani A; Oldani M; Giglio A; Ciambellotti F; Facchini M; Parati G; Malfatto G
    J Int Med Res; 2017 Feb; 45(1):361-371. PubMed ID: 28222634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
    Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
    Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
    Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.